Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Core Viewpoint - The FDA has approved Milestone's CARDAMYST nasal spray, marking a significant milestone for the company and its product portfolio [2]. Group 1: Company Overview - Milestone's President and CEO, Joe Oliveto, will provide opening remarks and discuss the product label details during the conference call [4]. - Dr. David Bharucha, the Chief Medical Officer, will address the medical need from a clinician's perspective [4]. - Lorenz Muller, the Chief Commercial Officer, will outline the launch plans for CARDAMYST nasal spray [4].